COVID-19 vaccine, mRNA (Pfizer-BioNTech; Comirnaty), is approved by the FDA as a primary (2-dose) series to prevent COVID-19 caused by the SARS-CoV-2 virus in people 12 years of age and older.
Information from clinical trials is available at this time to support the use of Pfizer-BioNTech COVID-19 vaccine to prevent COVID-19.
The FDA has also approved an EUA for the COVID-19 vaccine, mRNA, monovalent (Pfizer-BioNTech; Comirnaty) to allow:
- a two-dose primary series to children 5 through 11 years of age.
- a three-dose primary series to children 6 months through 4 years of age.
- a third dose in certain people 5 years of age and older who are immunocompromised (have a weakened immune system).
- a single booster dose to people 5–11 years of age who have completed a primary series with Pfizer-BioNTech COVID-19 vaccine.
The FDA has also approved an EUA for the COVID-19 vaccine, mRNA, bivalent for children and adults 12 years of age and older as a single booster dose given 2 months after either:
- a primary 2-dose vaccine series with any authorized or approved COVID-19 monovalent vaccine
- a booster dose of any authorized or approved COVID-19 monovalent vaccine
The FDA-approved COMIRNATY (COVID-19 Vaccine, mRNA) and the FDA-authorized Pfizer-BioNTech COVID-19 Vaccine, Monovalent under Emergency Use Authorization (EUA) for people 12 years of age and older can be used interchangeably to provide doses for COVID-19 primary vaccination or a booster dose. Booster eligibility and schedule are based on the approved information of the vaccine used for the primary series. The vaccine that is authorized for use in children 6 months through 4 years of age and in children 5 through 11 years of age includes the same mRNA and lipids at a lower dose but different inactive ingredients compared to the vaccine that has been used under EUA in individuals 12 years of age and older and that has been studied in clinical trials. The use of the different inactive ingredients helps stabilize the vaccine under refrigerated temperatures and the formulations can be readily prepared to deliver appropriate doses to the 6 month- through 11 year-old population.
Talk to your doctor or vaccine provider about the risks and benefits of receiving this medication.
What is COVID-19?
COVID-19 disease is caused by a coronavirus called SARS-CoV-2. You can get COVID-19 through contact with another person who has the virus. It is predominantly a respiratory (lung) illness, but it can also affect other organs. People with COVID-19 have had a wide range of symptoms reported, ranging from mild symptoms to severe illness leading to death. Symptoms may appear 2 to 14 days after exposure to the virus. Symptoms may include: fever, chills, cough, shortness of breath, fatigue, muscle or body aches, headache, loss of taste or smell, sore throat, congestion, runny nose, nausea, vomiting, or diarrhea.
How is the Pfizer-BioNTech COVID-19 vaccine given?
The COVID-19 mRNA, monovalent and bivalent vaccines will be given to you as an injection into the muscle. For individuals 5 years of age and older, the Pfizer-BioNTech COVID-19 monovalent vaccine primary vaccination series is 2 doses given 3 weeks apart. For children 6 months to 4 years of age, the Pfizer-BioNTech COVID-19 monovalent vaccine primary vaccination series is given as 2 doses at least 3 weeks apart followed by a third dose at least 8 weeks after the second dose. The doses for children 6 months–4 years of age and 5–11 years of age is lower than the dose used for people 12 years of age and older. If you receive one dose of the Pfizer-BioNTech COVID-19 monovalent vaccine, you should receive a second dose of this same vaccine 3 weeks later.
As authorized under an EUA, the Pfizer-BioNTech COVID-19 monovalent vaccine may be given as:
- a third dose 4 weeks after the second dose to people 5 years of age and older who are immunocompromised;
- a single booster dose at least 5 months after completion of a primary series with Pfizer-BioNTech COVID-19 vaccine to people 5–11years of age.
As authorized under an EUA, the COVID-19, mRNA, bivalent vaccine may be given as:
- a single booster dose given at least 2 months after the primary monovalent series is completed in people ages 12 and older
- a single booster dose given at least 2 months after a booster of any authorized or approved monovalent COVID-19 vaccine in people ages 12 and older
What should you tell the person who is giving the vaccine?
Tell your vaccine provider about all of your medical conditions, including if you:
- have any allergies.
- have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart).
- have a fever.
- have a bleeding disorder or are taking a blood thinner such as warfarin (Coumadin, Jantoven).
- have a weakened immune system or are on a medicine that affects your immune system.
- are pregnant or plan to become pregnant.
- are breast-feeding.
- have received another COVID-19 vaccine.
- have ever fainted in association with an injection.
- have had a severe allergic reaction after a previous dose of this vaccine.
- have had a serious allergic reaction to any ingredient in this vaccine.
What are the benefits of the Pfizer-BioNTech COVID-19 vaccine?
In an ongoing clinical trial, the Pfizer-BioNTech COVID-19 vaccine has been shown to prevent COVID-19 after getting 2 doses given 3 weeks apart. How long you are protected against COVID-19 is currently unknown.
What are the risks of the Pfizer-BioNTech COVID-19 vaccine?
Side effects that have been reported with the Pfizer-BioNTech COVID-19 vaccine include:
- non-severe allergic reactions such as rash, itching, hives, or swelling of the face
- injection site pain, swelling, and redness
- muscle pain
- joint pain
- feeling unwell
- swollen lymph nodes
- decreased appetite
- arm pain
- fainting at the time you receive your injection
There is a remote chance that the Pfizer-BioNTech COVID-19 vaccine could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to one hour after getting a dose of the Pfizer-BioNTech COVID-19 vaccine.
Signs of a severe allergic reaction can include:
- difficulty breathing
- swelling of your face and throat
- a fast heartbeat
- a bad rash all over your body
- dizziness and weakness
Myocarditis and pericarditis have occurred in some people who have received the Pfizer-BioNTech COVID-19 vaccine, more commonly in males under 40 years of age than among females and older males. In most of these people, symptoms began within a few days after getting the second dose of the Pfizer-BioNTech COVID-19 vaccine. The chance of having this occur is very low.
You should seek medical attention right away if you have any of the following symptoms after receiving the Pfizer-BioNTech COVID-19 vaccine:
- chest pain
- shortness of breath
- feelings of having a fast-beating, fluttering, or pounding heart
These may not be all the possible side effects of the Pfizer-BioNTech COVID-19 vaccine. Serious and unexpected side effects may occur. Pfizer-BioNTech COVID-19 vaccine is still being studied in clinical trials.
What should I do about side effects?
What you should do about side effects:
- If you experience a severe allergic reaction, call 9-1-1, or go to the nearest hospital.
- Call the vaccination provider or your healthcare provider if you have any side effects that bother you or do not go away.
- Report vaccine side effects to FDA/CDC Vaccine Adverse Event Reporting System (VAERS). The VAERS toll-free number is 1-800-822-7967 or report online to https://vaers.hhs.gov/reportevent.html. Please include either "COMIRNATY (COVID-19 Vaccine, mRNA)", "Pfizer-BioNTech COVID-19 Vaccine EUA", or "Pfizer-BioNTech COVID-19 Vaccine, Bivalent EUA" as appropriate, in the first line of box #18 of the report form.
- In addition, you can report side effects to Pfizer Inc. at http://www.pfizersafetyreporting.com or at 1-800-438-1985.
- You may also be given an option to enroll in v-safe. V-safe is a new voluntary smartphone-based tool that uses text messaging and web surveys to check in with people who have been vaccinated to identify potential side effects after COVID-19 vaccination. V-safe asks questions that help CDC monitor the safety of COVID-19 vaccines. V-safe also provides second-dose reminders if needed and live telephone follow-up by CDC if participants report a significant health impact following COVID-19 vaccination. For more information on how to sign up, visit: http://www.cdc.gov/vsafe.
What if I am immunocompromised?
Based on the EUA, if you are immunocompromised (have a weakened immune system), you may receive a third dose of the Pfizer-BioNTech COVID-19 vaccine 4 weeks after the second dose. The third dose may still not provide full immunity to COVID-19 in people who are immunocompromised, and you should continue to maintain physical precautions to help prevent COVID-19. In addition, your close contacts should be vaccinated as appropriate.
Will the Pfizer-BioNTech COVID-19 vaccine give me COVID-19?
No. The Pfizer-BioNTech COVID-19 vaccine does not contain SARS-CoV-2 and cannot give you COVID-19.
Keep your vaccination card
When you get your first dose, you will get a vaccination card to show you when to return for your next dose(s) of Pfizer-BioNTech COVID-19 vaccine. Remember to bring your card when you return.
Where will my vaccination information be recorded?
The vaccination provider may include your vaccination information in your state/local jurisdiction's Immunization Information System (IIS) or other designated system. This will ensure that you receive the same vaccine when you return for your next dose of Pfizer-BioNTech COVID-19 vaccine. For more information about IISs visit: https://www.cdc.gov/vaccines/programs/iis/about.html.
How can I learn more?
You can learn more by:
- Ask the vaccination provider.
- Visit CDC at https://www.cdc.gov/coronavirus/2019-ncov/index.html.
- Visit FDA at http://bit.ly/3qI0njF.
- Contact your local or state public health department.
Can I be charged an administration fee for receiving the COVID-19 vaccine?
No. At this time, the provider cannot charge you for a vaccine dose and you cannot be charged an out-of-pocket vaccine administration fee or any other fee if only receiving a COVID-19 vaccination. However, vaccination providers may seek appropriate reimbursement from a program or plan that covers COVID-19 vaccine administration fees for the vaccine recipient (private insurance, Medicare, Medicaid, HRSA COVID-19 Uninsured Program for non-insured recipients).
Where can I report cases of suspected fraud?
Individuals becoming aware of any potential violations of the CDC COVID-19 Vaccination Program requirements are encouraged to report them to the Office of the Inspector General, U.S. Department of Health and Human Services, at 1-800-HHS-TIPS or TIPS.HHS.GOV.
What is the Countermeasures Injury Compensation Program
The Countermeasures Injury Compensation Program (CICP) is a federal program that may help pay for costs of medical care and other specific expenses of certain people who have been seriously injured by certain medicines or vaccines, including this vaccine. Generally, a claim must be submitted to the CICP within one year from the date of receiving the vaccine. To learn more about this program, visit http://www.hrsa.gov/cicp/ or call 1-855-266-2427.
- BNT162b2 mRNA
- mRNA COVID-19 vaccine
- SARS-CoV-2 (COVID-19) vaccine, mRNA spike protein